Skeletal muscles constitute roughly 40% of human body mass. Muscles are specialized tissues that generate force to drive movements through ATP-driven cyclic interactions between the protein filaments, namely actin and myosin filaments. The filaments are organized in an intricate structure called the 'sarcomere', which is a fundamental contractile unit of striated skeletal and cardiac muscle, hosting a fine assembly of macromolecular protein complexes. The micrometer-sized sarcomere units are arranged in a reiterated array within myofibrils of muscle cells. The precise spatial organization of sarcomere is tightly controlled by several molecular mechanisms, indispensable for its force-generating function. Disorganized sarcomeres, either due to erroneous molecular signaling or due to mutations in the sarcomeric proteins, lead to human diseases such as cardiomyopathies and muscle atrophic conditions prevalent in cachexia. Protein post-translational modifications (PTMs) of the sarcomeric proteins serve a critical role in sarcomere formation (sarcomerogenesis), as well as in the steady-state maintenance of sarcomeres. PTMs such as phosphorylation, acetylation, ubiquitination, and SUMOylation provide cells with a swift and reversible means to adapt to an altered molecular and therefore cellular environment. Over the past years, SUMOylation has emerged as a crucial modification with implications for different aspects of cell function, including organizing higher-order protein assemblies. In this review, we highlight the fundamentals of the small ubiquitin-like modifiers (SUMO) pathway and its link specifically to the mechanisms of sarcomere assembly. Furthermore, we discuss recent studies connecting the SUMO pathway-modulated protein homeostasis with sarcomere organization and muscle-related pathologies.Abbreviations ASH2L, ASH2 Like, Histone Lysine Methyltransferase Complex Subunit; CapZ, F-actin capping protein; Ckm, creatine kinase M-type; cMyBP-C, cardiac myosin binding protein C; Ezh2, enhancer of zeste homolog 2; G9a, euchromatin histone methyltransferase 2; H3K27me3, trimethylation of lysine 27 on histone 3; HDAC, histone deacetylase; hMR-1, human myofibrillogenesis regulator 1; IFN, interferon; Suv39h1, suppressor of variegation 3-9 homolog 1; IjBa, inhibitor of kappa B; Mck, muscle creatine kinase; MEF2d, myocyte enhancer factor-2d; MLCK, myosin light chain kinase; MLL, mixed-lineage leukemia; MLP, muscle LIM protein; MRFs, the myogenic regulatory factors; Myf5, Myc-like basic helix-loop-helix transcription factor; MyHC IIb or Myh2, myosin heavy chain II; MyoD, myoblast determination factor; MYOG, myogenin; NMM II, nonmuscle myosin II; Nse2, non-structural maintenance of chromosome element 2 homolog; Pax7, paired-box 7; PCAF, p300/CBP-associated factor; PcG proteins, polycomb-group proteins; PRC, polycomb repressive complexes; PTMs, post-translational modifications; RLC, regulatory light chains; RNA Pol II, RNA polymerase II; ROS, reactive oxygen species; SAE 1/2, SUMO-activating enzyme 1 or 2; SAE1/2, SUMO E1-a...